Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation - Graham, DJ; Reichman, ME; Wernecke, M (JAMA Intern Med, 2016)
et al.